From the AGA Journals
From the AGA Journals
IL-23 plays key roles in antimicrobial macrophage activity
Human macrophages showed less antimicrobial activity when transfected with the IL23R-Q381 variant, which is protective against IBD.
From the Journals
Budesonide orodispersible tablets maintained remissions in EoE
After 48 weeks, 51 patients in the 1-mg group (75%) and 50 patients in the 0.5 mg group (73.5%) remained in remission, compared with only three...
From the Journals
Diarrhea prevalent among COVID-19 patients with IBD
One in five patients with IBD and COVID-19 had diarrhea, at least twice the prevalence compared with pooled data from prior studies.
From the Journals
A possible benchmark for Barrett’s esophagus surveillance
A study of neoplasia detection rate in community gastroenterology procedures could provide a quality control benchmark for surveillance in Barrett...
From the Journals
Real-world safety, efficacy found for fecal transplants
The study didn't yield any findings on indications other than Clostridioides difficile. "In no way, shape, or form does it mean you can use it for...
From the AGA Journals
AGA issues recommendations for pre-endoscopy coronavirus testing
Testing should balance local prevalence, false positives, false negatives, and endoscopist risk tolerance.
News
AGA addresses postendoscopy esophageal adenocarcinoma
While emerging technologies may improve detection rates in the future, short-term progress will depend on human expertise.
From the Journals
Lusutrombopag found safe, effective for severe thrombocytopenia in patients with hepatocellular carcinoma
Lusutrombopag met the primary efficacy endpoint and did not significantly increase the rate of postprocedural thromboses, compared with placebo....
News
AGA Clinical Practice Update: Diagnosis and treatment of small intestinal bacterial overgrowth
For now, a SIBO diagnosis simply means that a patient’s presenting symptoms or laboratory findings are attributed to bacterial changes in the...
From the AGA Journals
Bariatric surgery achieved long-term resolution of NASH without worsening fibrosis
In all, 84% of patients evaluated at 5 years met this primary endpoint.